Relypsa Inc. shares surged in the extended session Monday after the biotech said an early-stage study showed its treatment for elevated blood potassium did not interfere with other drugs. Relypsa shares rallied 7% to $20.93 on heavy volume. The company said its drug Veltassa did not interfere with absorption levels of 12 other drugs, according to the study. Veltassa is approved for the treatment of hyperkalemia, a condition that causes high potassium levels in the blood.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News